Search research articles
Contact Us
Filters
Showing results (671-680 of 715) with videos related to
Page
of 72
Sort By:
Hemasphere
|
August 20, 2025
Efficacy of idecabtagene vicleucel in patients with relapsed/refractory multiple myeloma and prior central nervous system manifestation: A multicenter real-world analysis
Markus Maulhardt, Simon Call, Hristo Boyadzhiev, et al.
Annals of Hematology
|
January 20, 2025
Impact of calreticulin mutations on treatment and survival outcomes in myelofibrosis during ruxolitinib therapy
Francesca Palandri, Filippo Branzanti, Erika Morsia, et al.
Biorxiv : the Preprint Server for Biology
|
April 3, 2026
Clonal Hematopoiesis Instructs Maladaptive Tissue Repair to Promote Fibrosis
Dongzhu Li, Ana C Viñado, Paula Garcia-Olloqui, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
June 24, 2015
The butterfly plant arms-race escalated by gene and genome duplications
Patrick P Edger, Hanna M Heidel-Fischer, Michaël Bekaert, et al.
Hematological Oncology
|
April 7, 2018
Epidemiology, outcome, and risk factors for infectious complications in myelofibrosis patients receiving ruxolitinib: A multicenter study on 446 patients
Nicola Polverelli, Giuseppe A Palumbo, Gianni Binotto, et al.
Molecular Cancer
|
December 4, 2023
Immunoproteasome function maintains oncogenic gene expression in KMT2A-complex driven leukemia
Nuria Tubío-Santamaría, Ashok Kumar Jayavelu, Tina M Schnoeder, et al.
Leukemia Research
|
June 3, 2025
Treatment strategies and survival after ruxolitinib discontinuation in myelofibrosis patients: The Italian RUX-MF multicenter study
Francesca Palandri, Massimo Breccia, Erika Morsia, et al.
Hematological Oncology
|
April 10, 2020
Risk factors for progression to blast phase and outcome in 589 patients with myelofibrosis treated with ruxolitinib: Real-world data
Francesca Palandri, Massimo Breccia, Mario Tiribelli, et al.
Cancer Research
|
June 17, 2024
Oncogenic Calreticulin Induces Immune Escape by Stimulating TGFβ Expression and Regulatory T-cell Expansion in the Bone Marrow Microenvironment
Dominik Schmidt, Cornelia Endres, Rouven Hoefflin, et al.
Cancer
|
August 21, 2025
Revised "iRR6" model in intermediate-1 risk myelofibrosis patients treated with ruxolitinib
Francesca Palandri, Filippo Branzanti, Massimiliano Bonifacio, et al.
Page
of 72
Search research articles
Search
Showing results (671-680 of 715) with videos related to
Sort By:
Page
of 72
Hemasphere
|
August 20, 2025
Efficacy of idecabtagene vicleucel in patients with relapsed/refractory multiple myeloma and prior central nervous system manifestation: A multicenter real-world analysis
Markus Maulhardt, Simon Call, Hristo Boyadzhiev, et al.
Annals of Hematology
|
January 20, 2025
Impact of calreticulin mutations on treatment and survival outcomes in myelofibrosis during ruxolitinib therapy
Francesca Palandri, Filippo Branzanti, Erika Morsia, et al.
Biorxiv : the Preprint Server for Biology
|
April 3, 2026
Clonal Hematopoiesis Instructs Maladaptive Tissue Repair to Promote Fibrosis
Dongzhu Li, Ana C Viñado, Paula Garcia-Olloqui, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
June 24, 2015
The butterfly plant arms-race escalated by gene and genome duplications
Patrick P Edger, Hanna M Heidel-Fischer, Michaël Bekaert, et al.
Hematological Oncology
|
April 7, 2018
Epidemiology, outcome, and risk factors for infectious complications in myelofibrosis patients receiving ruxolitinib: A multicenter study on 446 patients
Nicola Polverelli, Giuseppe A Palumbo, Gianni Binotto, et al.
Molecular Cancer
|
December 4, 2023
Immunoproteasome function maintains oncogenic gene expression in KMT2A-complex driven leukemia
Nuria Tubío-Santamaría, Ashok Kumar Jayavelu, Tina M Schnoeder, et al.
Leukemia Research
|
June 3, 2025
Treatment strategies and survival after ruxolitinib discontinuation in myelofibrosis patients: The Italian RUX-MF multicenter study
Francesca Palandri, Massimo Breccia, Erika Morsia, et al.
Hematological Oncology
|
April 10, 2020
Risk factors for progression to blast phase and outcome in 589 patients with myelofibrosis treated with ruxolitinib: Real-world data
Francesca Palandri, Massimo Breccia, Mario Tiribelli, et al.
Cancer Research
|
June 17, 2024
Oncogenic Calreticulin Induces Immune Escape by Stimulating TGFβ Expression and Regulatory T-cell Expansion in the Bone Marrow Microenvironment
Dominik Schmidt, Cornelia Endres, Rouven Hoefflin, et al.
Cancer
|
August 21, 2025
Revised "iRR6" model in intermediate-1 risk myelofibrosis patients treated with ruxolitinib
Francesca Palandri, Filippo Branzanti, Massimiliano Bonifacio, et al.
Page
of 72